Personalized Treatment for Invasive Ductal Breast Carcinoma with Lung and Liver Metastases Based on Patient-Derived Organoids: A Case Report

Patient-derived organoids (PDOs) are emerging as a potential preclinical tool in assessing cancer patients' responses to various therapies. Here, we first described a case of invasive ductal breast carcinoma with lung and liver metastases who obtained efficient response to the sensitive drugs identified by PDOs. A 54-year-old woman came to hospital with the chief complaint of an unpainful mass in the right breast. In combination with relevant examinations, she was diagnosed with cT3N1M0 breast cancer with HER2 amplification, but developed lung and liver metastases after use of multiple therapies. After treatment with erebulin, carboplatin and inetetamab sensitive revealed by the organoid drug sensitivity testing, partial response in lung metastasis and stable disease in liver metastasis were achieved. This typical case suggests that for the individual patients with advanced refractory breast cancer, especially those exhausting the standard treatment options, the PDOs may serve as an effective model for assessing individual drug sensitivity to optimize treatment decisions and improve treatment response.